A 42-Year-Old Woman Presented with a 1-Week History of Swelling and Pain in the Fifth Finger of Her Left Hand
Total Page:16
File Type:pdf, Size:1020Kb
A 42-year-old woman presented with a 1-week history of swelling and pain in the fifth finger of her left hand. She reported no related trauma. She had systemic lupus erythematosus, treated with mycophenolate mofetil and prednisone. Physical examination of the affected finger revealed soft-tissue swelling, with erythema and warmth, that was most prominent between the proximal and distal interphalangeal joints, sparing the fingertip. The patient’s husband had recently traveled to China and developed a cough soon after his return home. What is the cause of the patient’s finger swelling? Acute gout The answer is extrapulmonary manifestation of Flare of systemic lupus erythematosus tuberculosis. Examination of a biopsy specimen of the deep dermis after Fite staining revealed Septic arthritis numerous acid-fast bacilli. Culture of a tissue sample grew Mycobacterium tuberculosis. Extrapulmonary manifestation of Although infection of the finger is a rare tuberculosis extrapulmonary manifestation of tuberculosis, it is an important consideration in Osteoarthritis immunosuppressed patients. This patient was treated with a four-drug antituberculosis regimen for a total of 9 months and had complete resolution of her symptoms. Oxycodon wurde 1916 von Martin Freund (1863–1920) und Edmund Speyer (1878–1942) an der Universität Frankfurt/Main entwickelt und ein Jahr später von Merck in Darmstadt unter dem Namen Eukodal als schmerZ- und hustenstillendes Mittel auf den Markt gebracht. Seit 1919 wurde es als Analgetikum therapeutisch genutZt. Eukodal war bis 1990 in Deutschland im Handel und wurde wegen des sehr hohen Sucht- und Missbrauchspotentials vom Markt genommen. Die ersten Fälle von Oxycodon-Missbrauch, der in Analogie Zum Morphinismus Eukodalismus genannt wird, wurden Zu Beginn der 1920er Jahre geschildert. Der US- amerikanische Pharmakonzern Purdue Pharma L.P. wurde im Jahr 2007 Zu 634,5 Mio. US-Dollar Strafe verurteilt, weil er in der Packungsbeilage nicht ausreichend gekennzeichnet hatte, dass Oxycodon wie andere Opioide ein hohes Abhängigkeitspotenzial besitZt. 2010 lag Oxycontin, das seit den 1990er Jahren aggressiv beworben worden war, in den Vereinigten Staaten auf PlatZ fünf der umsatZstärksten Medikamente. Der Umsatz betrug über 3,5 Mrd. US- Dollar. Der US-Staat Florida kämpft seit 2010 gegen sog. pill mills, Schmerzkliniken, in denen Opioide wie Oxycontin verschrieben werden. Durch staatliche Regulierung wurde die Verfügbarkeit seither verringert. Allerdings ist dafür ein illegaler Handel mit der Substanz aufgeblüht, und viele Oxycontin-Abhängige sind überdies auf Heroin umgestiegen, da es inzwischen günstiger und teilweise auch besser verfügbar ist. https://www.newyorker.com/magazine/2017/10/30/the- family-that-built-an-empire-of-pain Within five years of its introduction, OxyContin was generating a billion dollars a year. “There is no sign of it slowing down,” Richard Sackler told a team of company representatives in 2000. The sales force was heavily incentivized to push the drug. In a memo, a sales manager in Tennessee wrote, “$$$$$$$$$$$$$ It’s Bonus Time in the Neighborhood!” May, who was assigned to the Virginia area, was astonished to learn that especially skillful colleagues were earning hundreds of thousands of dollars in commissions. One year, May’s own sales were so brisk that Purdue rewarded him with a trip to Hawaii. As prescriptions multiplied, Purdue executives—and the Sackler family members on the company’s board—appeared happy to fund such blandishments. Internal budget plans described the company’s sales force as its “most valuable resource.” In 2001, Purdue Pharma paid forty million dollars in bonuses. The Tobacco Master Settlement Agreement — Strategic Lessons for Addressing Public Health Problems The 1998 Master Settlement Agreement (MSA) between the tobacco industry and 46 state attorneys general (Ags), five U.S. territories, and Washington, D.C., remains the largest legal settlement ever executed in the United States. The MSA achieved important public health objectives, including substantially reduced smoking rates and lives saved.1 Given its success, the agreement has enormous promise as a model for similar litigation or settlements that could hold industries accountable when they knowingly deceive and injure consumers with their products. Most opioid prescription deaths occur among people with common conditions for which prescribing risks outweigh benefits. General psychological insights offer an explanation: People may judge risk to be low without available personal experiences, may be less careful than expected when not observed, and may falter without an injunction from authority. To test these hypotheses, we conducted a randomiZed trial of 861 clinicians prescribing to 170 persons who subsequently suffered fatal overdoses. Clinicians in the intervention group received notification of their patients’ deaths and a safe prescribing injunction from their county’s medical examiner, whereas physicians in the control group did not. Milligram morphine equivalents in prescriptions filled by patients of letter recipients versus controls decreased by 9.7% (95% confidence interval: 6.2 to 13.2%; P < 0.001) over 3 months after intervention. We also observed both fewer opioid initiates and fewer high-dose opioid prescriptions by letter recipients. Decedent characteristics.OTC, over the counter; n, number of clinicians. Prescriber characteristics. Adjusted daily average milligram morphine equivalents (MMEs) dispensed per prescriber among persons randomiZed to the intervention or control groups. Transthyretin (TTR) is a transport protein in the serum and cerebrospinal fluid that carries the thyroid hormone thyroxine (T4) and retinol-binding protein bound to retinol. This is how transthyretin gained its name: transports thyroxine and retinol. The liver secretes transthyretin into the blood, and the choroid plexus secretes TTR into the cerebrospinal fluid. TTR was originally called prealbumin (or thyroxine-binding prealbumin) because it ran faster than albumin on electrophoresis gels. Tafamidis (trade name Vyndaqel) is a drug used to delay loss of peripheral nerve function in adults with familial amyloid polyneuropathy (FAP), an orphan disease. It works by stabiliZing the protein, transthyretin, which is normally made up of four strands. In people with FAP these strands separate and form clumps that harm nerves. Tafamidis functions as a chaperone that stabiliZes the correctly folded tetrameric form of the transthyretin (TTR) protein by binding in one of the two thyroxine-binding sites of the tetramer. In people with FAP, the individual monomers fall away from the tetomer, misfold, and aggregate; the aggregates harm nerves. The maximum plasma concentration is achieved around 2 hours after dosing; in plasma it is almost completely bound to proteins. Based on preclinical data, it appears to be metabolized by glucuronidation and excreted via bile; in humans, around 59% of a dose is recovered in feces, and approximately 22% in urine. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and amyloidogenesis. In a multicenter, international, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 441 patients with transthyretin amyloid cardiomyopathy in a 2:1:2 ratio to receive 80 mg of tafamidis, 20 mg of tafamidis, or placebo for 30 months. In the primary analysis, we hierarchically assessed all-cause mortality, followed by frequency of cardiovascular-related hospitaliZations according to the Finkelstein–Schoenfeld method. Key secondary end points were the change from baseline to month 30 for the 6-minute walk test and the score on the Kansas City Cardiomyopathy Questionnaire– Overall Summary (KCCQ-OS), in which higher scores indicate better health status. Primary Analysis and Components. Panel A shows the results of the primary analysis as determined with the use of the Finkelstein– Schoenfeld method. Panel B shows an analysis of all-cause mortality for pooled tafamidis and for placebo, a secondary end point. Panel C shows the frequency of cardiovascular- related hospitaliZations, also a secondary end point. Overall and Subgroup Results as Calculated with the Use of the Finkelstein–Schoenfeld Method, All-Cause Mortality, and Cardiovascular-Related HospitaliZations. All-cause mortality was evaluated with the use of a Cox proportional-hazards model, with treatment and stratification factors treated as covariates. The survival analysis interaction terms are based on a post hoc analysis. The frequency of cardiovascular-related hospitaliZations was assessed with the use of a Poisson regression model. ATTRm denotes disease that results from an inherited autosomal dominant trait that is caused by pathogenic mutations in TTR, ATTRwt disease that results from the deposition of wild-type transthyretin protein, and NYHA New York Heart Association. Key Secondary End Points. Panel A shows the least-squares (LS) mean (±SE) change from baseline to month 30 in the distance walked in the 6-minute walk test in the pooled tafamidis group as compared with the placebo group. Panel B shows the LS mean (±SE) change from baseline for both groups in the Kansas City Cardiomyopathy Questionnaire–Overall Summary (KCCQ- OS) score, in